Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study

Authors:
Open Access
Publisher website
Google Scholar
Abstract
No abstract available
Funding Information
  • European Association for the Study of the Liver
  • European Society for Medical Oncology
  • Imperial Experimental Cancer Medicine Centre
  • Ministry of Science and ICT, South Korea (2023R1A2C2004339)
  • Cancer Research UK (RCCPDB-Nov21/100008)
  • Wellcome Trust
  • National Research Foundation of Korea
  • NIHR Imperial Biomedical Research Centre
  • National Institute on Handicapped Research
  • Cancer Treatment and Research Trust
  • Eisai

This publication has 36 references indexed in Scilit: